Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

August 18, 2017

Study Completion Date

August 18, 2017

Conditions
Peanut Allergy
Interventions
BIOLOGICAL

Viaskin Peanut 250mcg

Peanut extract cutaneous patch

BIOLOGICAL

Placebo

Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract

Trial Locations (31)

10029

Jaffe Food Allergy Institute, New York

15213

Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

21287

Johns Hopkins Hospital, Baltimore

27599

The University of North Carolina - Chapell Hill, Chapel Hill

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

72202

Arkansas Children's Hospital, Little Rock

75235

Children's Medical Center of Dallas, Dallas

77030

Baylor College of Medicine - Texas Children's Hospital, Houston

80045

Children's Hospital Colorado, Aurora

80206

National Jewish Health, Denver

92123

University of California, Rady Children's Hospital, San Diego

94305

Stanford University School of Medicine, Stanford

98115

ASTHMA, Inc., Seattle

02114

Massachusetts General Hospital, Boston

02115

Boston Childrens' Hospital, Boston

Unknown

Allergy Medical, Brisbane

Princess Margaret Hospital for Children, Perth

Children's Hospital Westmead, Sydney

Universitätsklinikum Erlangen, Erlangen

Clinical Investigations Unit, Cork

Our Lady's Children's Hospital, Dublin

V5H 3V4

British Columbia Children's Hospital, Vancouver

L5A 3V4

Cheema Research Inc., Mississauga

K1Y 4G2

Ottawa Allergy Asthma Research Institute, Ottawa

M4V 1R2

Gordon Sussman Clinical Research Inc., Toronto

H3T 1C4

CHUM & CHU Sainte-Justine, Montreal

QC G1V4M6

Centre de Recherche Appliquée en Allergie de Québec (CRAAQ), Québec

D-13353

Charité Universitätsmedizin Berlin, Berlin

D-53115

St.-Marien-Hospital, Bonn

Sponsors

Lead Sponsor

All Listed Sponsors
lead

DBV Technologies

INDUSTRY

NCT02636699 - Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy | Biotech Hunter | Biotech Hunter